证券日报网讯 1月15日，京新药业在互动平台回答投资者提问时表示，公司会依据相关法律法规及公司 信披管理制度，做好信息披露工作。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 1月15日，京新药业在互动平台回答投资者提问时表示，公司JX2201美国暂未开展临床试 验，具体进展敬请关注相关公告。 ...

格隆汇1月15日丨京新药业(002020.SZ)在互动平台表示，深圳巨烽主要提供医用显示模块解决方案，公 司会应用最新技术协助研发工作，但是在类人脑方面暂未有布局。 ...

（记者 张明双） 京新药业（002020.SZ）1月15日在投资者互动平台表示，公司JX2201美国暂未开展临床试验，具体进 展敬请关注相关公告。 每经AI快讯，有投资者在投资者互动平台提问：公司JX2201国内已进入I期临床，美国IND获批，是不 是意味着可以在美国开展临床试验了？是不是公司海外授权的目标公司是美国药企？ ...

Core Insights - Pfizer's stock has declined nearly 5% in a month, resulting in a loss of $7.3 billion in market capitalization due to disappointing financial guidance for 2026 [1][10] Financial Guidance - Pfizer expects total revenues for 2026 to be between $59.5 billion and $62.5 billion, a decline from the revised 2025 revenue expectation of around $62 billion [2] - Adjusted earnings per share for 2026 are projected to be in the range of $2.80-$3.00, down from the 2025 expected range of $3.00 and $3.15 [3] Oncology Business - Pfizer is a leading player in oncology, with oncology sales accounting for approximately 28% of total revenues [4][5] - Oncology revenues increased by 7% in the first nine months of 2025, driven by products like Xtandi and Padcev [5][10] - The company aims to have eight or more blockbuster oncology medicines by 2030 [5] Product Development and Acquisitions - Pfizer is expanding its product labels and has in-licensed rights to develop new oncology treatments, including a dual PD-1 and VEGF inhibitor [6][7] - Non-COVID operational revenues are improving, with new and acquired products expected to deliver double-digit growth in 2026 [8] - Pfizer invested approximately $1.6 billion in business development transactions in 2025, including the acquisition of Metsera [9] COVID Product Sales Decline - Sales of COVID products, Comirnaty and Paxlovid, are declining due to lower vaccination and infection rates [12][14] - Pfizer anticipates COVID revenues to be around $5 billion in 2026, down from about $6.5 billion in 2025 [10][14] Upcoming Challenges - Pfizer faces significant revenue impacts from the loss of exclusivity for key products between 2026 and 2030, expected to reduce sales by approximately $1.5 billion in 2026 [15] - The redesign of Medicare Part D under the Inflation Reduction Act is also expected to negatively affect revenues [16] Stock Performance and Valuation - Pfizer's stock has underperformed compared to the industry and the S&P 500, losing 4.8% over the past year [17] - The stock is currently trading at a price/earnings ratio of 8.36, significantly lower than the industry average of 17.81 [19] Analyst Sentiment - The Zacks Consensus Estimate for 2026 earnings has decreased from $3.15 to $3.02 per share over the past 60 days, reflecting a pessimistic outlook [22][26]

Core Viewpoint - Jingxin Pharmaceutical announced plans to issue overseas listed shares (H-shares) and apply for listing on the main board of the Hong Kong Stock Exchange to enhance its global strategy, international image, and overall competitiveness [1]. Group 1 - The company aims to deepen its globalization strategy [1] - The issuance of H-shares is part of the company's efforts to improve its international image [1] - The listing on the Hong Kong Stock Exchange is intended to increase the company's comprehensive competitiveness [1]

Summary of the Conference Call for Jinxin Pharmaceutical Industry Overview - Jinxin Pharmaceutical focuses on generic drugs, active pharmaceutical ingredients (APIs), and medical devices, with a strong presence in the CNS and cardiovascular sectors. The impact of centralized procurement has gradually diminished, allowing for stable growth in traditional pharmaceutical business [2][3][5]. Key Points Traditional Pharmaceutical Business - The traditional business includes generic drugs, APIs, and medical devices, with generics being the largest revenue contributor. The company has overcome the pressures from centralized procurement, and major products are expected to maintain steady growth [3][5]. - The integration of APIs and formulations provides cost advantages, and the acquisition of Shenzhen Jufeng has strengthened its position in the medical device market [2][5]. Innovative Drug Development - **Dazaxine (地达西尼)**: A new generation insomnia treatment that avoids safety issues associated with traditional benzodiazepines. It has shown rapid market uptake, with sales reaching 110 million RMB in the first three quarters of 2025, exceeding market expectations. It is expected to experience significant growth in 2026 and 2027 [2][6][8]. - **JX2,201**: A novel small molecule targeting lipid reduction, currently in phase II clinical trials. While it may not contribute significantly to short-term revenue, it has substantial business development (BD) potential and is expected to be a key driver of long-term growth [2][7]. Market Position and Competitive Landscape - Dazaxine competes with three major insomnia treatments, including those from Eisai and Shionogi. Its unique mechanism allows for rapid onset of action and minimal interaction with other medications, making it suitable for patients with multiple comorbidities [6][8]. - Jinxin's small molecule LPA innovation drug has a similar structure to Eli Lilly's drug, which is in phase III trials. If successful, it could enhance Jinxin's market position and BD potential [9]. Future Outlook - The company is expected to maintain steady growth in its traditional business due to the resolution of centralized procurement impacts. The rapid commercialization of Dazaxine and the promising outlook for the small molecule LPA drug contribute to a favorable investment profile [11]. - The potential for significant BD transactions for the LPA drug is highlighted, with upfront payments estimated between 100 to 200 million USD and total deals potentially reaching 2 billion USD [4][11]. Additional Insights - The differences between small molecule and small nucleic acid LPA-targeting drugs lie in their administration methods and mechanisms of action, with no significant efficacy differences reported so far [10]. - The company’s strategic focus on both traditional and innovative drug segments positions it well for future growth and investment opportunities [3][11].

转自：新华财经 •政府投资基金"投向哪、怎么投、谁来管" 国家首次作出系统规范 提出14项政策举措 •国务院办公厅12日对外发布《"高效办成一件事"2026年度第一批重点事项清单》，包含个人和经营主体事项共13项。新一批清单聚焦企业和个人全生命周 期高频事项，既涵盖科技型企业创新政策扶持、知识产权保护、举办体育赛事活动等赋能发展的"大事"，也包含育儿补贴申领、灵活就业参保等贴近生活 的"小事"，更有外籍来华人员办理电话卡、海船开航等服务开放的"新事"。（新华社） •中共中央政治局委员、国务院副总理何立峰12日在人民大会堂会见美国前财长、华平集团主席盖特纳时表示，中国正全面贯彻落实中共二十届四中全会精 神，按照"十五五"规划建议部署，纵深推进全国统一大市场建设，坚定不移扩大高水平对外开放，促进经济高质量发展。欢迎包括华平集团在内的外资企业 和长期资本继续扩大在华投资，深化对华互利合作。（新华社） •国家发展改革委等部门印发的《关于加强政府投资基金布局规划和投向指导的工作办法（试行）》12日对外发布，《工作办法》围绕政府投资基金"投向 哪、怎么投、谁来管"三方面，提出14项政策举措。在优化基金布局方面，要求基金支 ...

上述提案已于2026年1月12日经公司第九届董事会第三次会议审议通过，具体内容详见公司于2026年1月 13日在巨潮资讯网http://www.cninfo.com.cn披露的相关公告。 1、对中小投资者单独计票的议案：1-14；根据《公司章程》《股东会议事规则》和《深圳证券交易所 上市公司自律监管指引第1号一一主板上市公司规范运作》相关规定，本次股东会审议涉及中小投资者 利益的议案，公司对中小投资者的表决单独计票，单独计票结果将及时公开披露（中小投资者是指除上 市公司董事、高级管理人员以及单独或者合计持有公司5%以上股份的股东以外的其他股东）。 1、会议登记时间：2026年1月26日和2026年1月27日（8:00－11:00，14:00－16:00）（信函以收到邮戳 为准）。 2、登记办法： 2、特别决议议案：1-9，需经出席股东会股东（包括股东代理人）所持表决权三分之二以上通过。其余 提案均为普通表决事项，需经出席股东会的股东（包括股东代理人）所持表决权的二分之一以上通过； 3、涉及关联股东回避表决的议案：13；应回避表决的关联股东名称：本次投保责任保险涉及的相关公 司股东及其关联方。 4、涉及优先股股 ...

京新药业（002020）(002020.SZ)公告，公司拟发行境外上市股份(H股)并申请在中国香港联交所主板挂 牌上市。 ...